Join the Oncology Voice Network. Join for Free
The MSL Secret Weapon for Insightful Engagement
MSL secret weapon insightful engagement curiosity mindset KOL interactions powerful questions

The MSL Secret Weapon for Insightful Engagement


Share This Article


Summary

In this week’s episode, Mary Winkels, Global Director, Medical Affairs Training and Capability at Vertex Pharmaceuticals discusses the MSL secret weapon for insightful engagement.

Learn more about…

👉 What is the MSL “secret weapon” for insightful engagement
👉 How MSLs can build the curiosity and question asking muscle
👉 The skill gap for most MSLs in KOL interactions
👉 The art of asking powerful questions
👉 The value created by developing a curiosity mindset

Click for Source
MSL secret weapon, insightful engagement, curiosity mindset, KOL interactions, powerful questions

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The Power of Non Traditional KOL Engagement
Partner Avatar MSL Talk: Tom Caravela, Lindsey Harrer

The Power of Non Traditional KOL Engagement

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN